吡柔比星与卡介苗交替灌注预防浅表性膀胱癌术后复发的疗效观察  

Curative Effect Observation of Preventing Bladder Carcinoma Recidivation after Operati on by Perfusing Pirarubicin and Bacille Calmette Guerin in Turn

作　　者：宋光庆[1] 罗俊卿[1] 宋小军[2] 

机构地区：[1]武警湖南总队医院 [2]武警湖南总队卫生处,湖南长沙410006

出　　处：《临床军医杂志》2009年第6期988-989,共2页Clinical Journal of Medical Officers

摘　　要：目的观察吡柔比星（THP）与卡介苗（BCG）交替灌注的化学免疫疗法预防浅表性膀胱癌术后复发的疗效。方法将128例行经尿道膀胱癌电切术的浅表性膀胱癌患者,随机分为3组：Ⅰ组行THP与BCG交替灌注（48例）、Ⅱ组行THP灌注（40例）、Ⅲ组行BCG灌注（40例）,随访5年,比较三组肿瘤复发率。结果随访18月5年,平均4.2年,三组患者复发率分别为8.3%（4/48）、17.5%（7/40）和20%（8/40）,Ⅱ、Ⅲ组比较差异无统计学意义（P〉0.05）,Ⅰ组复发率低于Ⅱ、Ⅲ组（P〈0.05）。结论吡柔比星与卡介苗交替灌注的化学免疫疗法明显降低了浅表性膀胱癌的术后复发率,优于单用化疗药物或免疫制剂。Objective To observe the effect of preventing bladder carcinoma recidivation after surgical operation by perfusing pirarubicin and bacille calmette guerin in turn.Methods A total of 128 patients with bladder carcinoma after TUR-Bt were divided into three groups at random,i.e.Group A（perfusing pirarubicin and bacille calmette guerin in turn）,Group B（perfusing pirarubicin） and Group C（perfusing bacille calmette guerin）.Their relapse rates in five years were compared.Results After 18 months to 5 years＇ follow-up visit（4.2 years in average）,it was founded that the relapse rates were 8.3%（4/48）,17.5%（7/40） and 20%（8/40） respectively in Group A,Group B and Group C.The relapse rate of Group A was lower than that of Group B or Group C（P〈0.05）.Conclusion The chemoimmunotherapy of preventing bladder carcinoma recidivation by perfusing pirarubicin and bacille calmette guerin in turn is better than chemotherapeutics or immunotherapy alone.

关 键 词：浅表性膀胱癌 吡柔比星 卡介苗 膀胱灌注 

分 类 号：R737.14[医药卫生—肿瘤]